MAP2K1 and TRIB1

Data Source:
HPRD (in vivo)

		MAP2K1	TRIB1
Description		mitogen-activated protein kinase kinase 1	tribbles pseudokinase 1
Image
GO Annotations	Cellular Component	Nucleus Mitochondrion Early Endosome Late Endosome Endoplasmic Reticulum Golgi Apparatus Microtubule Organizing Center Cytosol Plasma Membrane Focal Adhesion	Nucleus Cytoplasm
	Molecular Function	Protein Kinase Activity Protein Serine/threonine Kinase Activity MAP Kinase Kinase Activity Protein Serine/threonine/tyrosine Kinase Activity Protein Tyrosine Kinase Activity MAP-kinase Scaffold Activity Protein Binding ATP Binding Protein C-terminus Binding Protein Serine/threonine Kinase Activator Activity Protein N-terminus Binding Scaffold Protein Binding	Protein Kinase Activity Protein Kinase Inhibitor Activity Protein Binding ATP Binding Transcription Factor Binding Mitogen-activated Protein Kinase Kinase Binding Ubiquitin Protein Ligase Binding Ubiquitin-protein Transferase Regulator Activity
	Biological Process	MAPK Cascade Activation Of MAPK Activity Protein Phosphorylation Chemotaxis Cell Cycle Arrest Signal Transduction Heart Development Negative Regulation Of Cell Population Proliferation Positive Regulation Of Gene Expression Negative Regulation Of Gene Expression Peptidyl-threonine Phosphorylation Peptidyl-tyrosine Phosphorylation Cerebellar Cortex Formation Neuron Differentiation Keratinocyte Differentiation Thyroid Gland Development Regulation Of Stress-activated MAPK Cascade Positive Regulation Of Transcription, DNA-templated Thymus Development Regulation Of Axon Regeneration Cell Motility Positive Regulation Of Axonogenesis Bergmann Glial Cell Differentiation Face Development Trachea Formation Epithelial Cell Proliferation Involved In Lung Morphogenesis Placenta Blood Vessel Development Labyrinthine Layer Development ERK1 And ERK2 Cascade Positive Regulation Of ERK1 And ERK2 Cascade Positive Regulation Of Protein Serine/threonine Kinase Activity Regulation Of Golgi Inheritance Cellular Senescence Positive Regulation Of Production Of MiRNAs Involved In Gene Silencing By MiRNA Regulation Of Early Endosome To Late Endosome Transport	Protein Phosphorylation Negative Regulation Of Protein Kinase Activity JNK Cascade Negative Regulation Of Smooth Muscle Cell Migration Negative Regulation Of Lipopolysaccharide-mediated Signaling Pathway Positive Regulation Of Proteasomal Ubiquitin-dependent Protein Catabolic Process Response To Lipopolysaccharide Regulation Of MAP Kinase Activity Negative Regulation Of DNA-binding Transcription Factor Activity Positive Regulation Of Eosinophil Differentiation Positive Regulation Of Macrophage Differentiation Negative Regulation Of Neutrophil Differentiation Negative Regulation Of Smooth Muscle Cell Proliferation
Pathways		MAPK3 (ERK1) activation Frs2-mediated activation Signal transduction by L1 Uptake and function of anthrax toxins RAF activation MAP2K and MAPK activation Negative feedback regulation of MAPK pathway MAP3K8 (TPL2)-dependent MAPK1/3 activation Signaling by moderate kinase activity BRAF mutants Signaling by high-kinase activity BRAF mutants Signaling by BRAF and RAF fusions Paradoxical activation of RAF signaling by kinase inactive BRAF Signaling downstream of RAS mutants Signaling by MAP2K mutants Signaling by RAF1 mutants	NGF-stimulated transcription
Drugs		K-252a 5-Bromo-N-[(2S)-2,3-dihydroxypropoxy]-3,4-difluoro-2-[(2-fluoro-4-iodophenyl)amino]benzamide Cobimetinib Bosutinib (5S)-4,5-difluoro-6-[(2-fluoro-4-iodophenyl)imino]-N-(2-hydroxyethoxy)cyclohexa-1,3-diene-1-carboxamide 2-[(2-chloro-4-iodophenyl)amino]-N-{[(2R)-2,3-dihydroxypropyl]oxy}-3,4-difluorobenzamide PD-0325901 N-(5-{3,4-difluoro-2-[(2-fluoro-4-iodophenyl)amino]phenyl}-1,3,4-oxadiazol-2-yl)ethane-1,2-diamine 2-[(4-ETHYNYL-2-FLUOROPHENYL)AMINO]-3,4-DIFLUORO-N-(2-HYDROXYETHOXY)BENZAMIDE Trametinib Selumetinib
Diseases		Noonan syndrome and related disorders, including: Noonan syndrome (NS); Leopard syndrome (LS); Noonan syndrome-like with loose anagen hair (NS/LAH); CBL-mutation associated syndrome (CBL); Neurofibromatosis type 1 (NF1); Neurofibromatosis type 2 (NF2); Neurofibromatosis-Noonan syndrome (NFNS); Legius syndrome; Cardiofaciocutaneous syndrome (CFCS); Costello syndrome (CS)
GWAS		Prostate cancer ( 29892016) Testicular germ cell tumor ( 28604728 28604732)	Adiponectin levels ( 22479202) Adult body size ( 32376654) Alanine transaminase levels ( 29403010) Apolipoprotein A1 levels ( 32203549) Apolipoprotein B levels ( 32203549) Birth weight ( 31043758 27680694) C-reactive protein levels ( 30388399) C-reactive protein levels or LDL-cholesterol levels (pleiotropy) ( 27286809) Carotid intima media thickness x smoking interaction ( 32117412) Cholesterol ( 31902109) Cholesterol, total ( 24097068 19060911 25961943 20686565 26582766) Coronary artery disease ( 32469254 26343387 33020668) Coronary artery disease (myocardial infarction, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease) ( 28714975) Diastolic blood pressure ( 27841878) Estimated glomerular filtration rate ( 31152163 31015462 30604766) Fractures (paediatric) ( 32742401) Gamma glutamyl transferase levels ( 29403010) Glycine levels ( 31070104 30837465) HDL cholesterol ( 24097068 25961943 20686565) HDL Cholesterol - Triglycerides (HDLC-TG) ( 21386085) HDL cholesterol levels ( 32203549 28334899 30698716) HDL cholesterol levels in current drinkers ( 30698716) HDL cholesterol levels x alcohol consumption (drinkers vs non-drinkers) interaction (2df) ( 30698716) HDL cholesterol levels x alcohol consumption (regular vs non-regular drinkers) interaction (2df) ( 30698716) Hypertriglyceridemia ( 27599772) Inflammatory bowel disease ( 23128233) LDL cholesterol ( 24097068 20864672 19060911 25961943 20686565) LDL cholesterol levels ( 32203549 28334899 30698716) LDL cholesterol levels in current drinkers ( 30698716) LDL cholesterol levels x alcohol consumption (drinkers vs non-drinkers) interaction (2df) ( 30698716) LDL cholesterol levels x alcohol consumption (regular vs non-regular drinkers) interaction (2df) ( 30698716) Lipid metabolism phenotypes ( 19936222) Lipid traits ( 24386095) Liver enzyme levels (alanine transaminase) ( 22001757) Liver enzyme levels (alkaline phosphatase) ( 22001757) Low density lipoprotein cholesterol levels ( 29403010) Metabolic syndrome ( 31589552) Metabolite levels ( 23823483) Metabolite levels (lipoprotein measures) ( 27005778) Microalbuminuria ( 31511532) Mosquito bite size ( 28199695) Myocardial infarction ( 26343387) Nonalcoholic fatty liver disease ( 31311600) Obesity-related traits ( 23251661) Response to statin therapy ( 20339536) Rosacea symptom severity ( 29771307) Serum alkaline phosphatase levels ( 29403010) Serum metabolite levels ( 31636271) Serum metabolite levels (CMS) ( 31636271) Serum total protein level ( 29403010) Systolic blood pressure ( 27841878) Total cholesterol levels ( 28334899 29403010) Triglyceride levels ( 32203549 28334899 31647587 30911093 29403010 30698716) Triglyceride levels in current drinkers ( 30698716) Triglyceride levels x alcohol consumption (drinkers vs non-drinkers) interaction (2df) ( 30698716) Triglyceride levels x alcohol consumption (regular vs non-regular drinkers) interaction (2df) ( 30698716) Triglycerides ( 24097068 18193043 18193044 20864672 19060906 24886709 20139978 25961943 26780889 20686565 26582766) Triglycerides-Blood Pressure (TG-BP) ( 21386085) Type 2 diabetes ( 32499647) Urinary albumin excretion ( 30220432) Urinary albumin excretion (no hypertensive medication) ( 30220432) Urinary albumin-to-creatinine ratio ( 31630189 30910378 31511532) Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour) ( 28443625) Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction) ( 28443625) Waist-to-hip ratio adjusted for BMI in non-smokers ( 28443625) White blood cell count (basophil) ( 29403010)
Interacting Genes		67 interacting genes: APC ARAF AURKA BANP BAX BIRC6 BMPR1A BRAF BUB1 CASP9 CDH1 CDK5 CDKN2A CPNE1 CPNE4 CTNNA1 EGFR ELK1 EP300 ERBB2 FBXW7 GRB10 HNRNPD HRAS KAT7 KSR1 KSR2 LAMTOR3 MAP3K4 MAP3K8 MAPK1 MAPK14 MAPK3 MAPK8 MAPK8IP3 MBP MLH3 MSH6 MYC ODC1 PAK1 PARVA PDGFRL PEBP1 PEBP4 PIK3CA PLEKHF2 PLK3 PPARG PRKCI PRKCZ PTPRJ RAF1 RPS6KA2 RPS6KA4 SMAD2 SRC STK11 TCP11 TGFBR2 TLR2 TRAF3 TRAF6 TRIB1 UBE2I UBE2L3 WNK1	8 interacting genes: ALOX12 CEBPB CEBPD CEBPE COP1 MAP2K1 MAP2K4 MAP2K7
Entrez ID		5604	10221
HPRD ID		01469	09863
Ensembl ID		ENSG00000169032	ENSG00000173334
Uniprot IDs		A4QPA9 B4DFY5 H3BRW9 Q02750	Q96RU8
PDB IDs		1S9J 2P55 3DV3 3DY7 3E8N 3EQB 3EQC 3EQD 3EQF 3EQG 3EQH 3EQI 3MBL 3ORN 3OS3 3PP1 3SLS 3V01 3V04 3VVH 3W8Q 3WIG 3ZLS 3ZLW 3ZLX 3ZLY 3ZM4 4AN2 4AN3 4AN9 4ANB 4ARK 4LMN 4MNE 4U7Z 4U80 4U81 5BX0 5EYM 5HZE 5YT3 6NYB 6PP9 6Q0J 6Q0T 6U2G 6X2P 6X2S 6X2X	5CEK 5CEM 5IGO 5IGQ 6DC0
Enriched GO Terms of Interacting Partners?
Tagcloud ?
Tagcloud (Difference) ?
Tagcloud (Intersection) ?